This is the authors' abstract. We don't add key points for this paper.
Background and Purpose: Cancer stem cells (CSCs) are a type of cancer cell owning the characteristic of self-renew and differentiation.We hypothesize that the stemness properties in CD44v6+ hepatocellular carcinoma cells (HCC) is promoted via the Met/cjun/Nanog signaling pathway, thus, serves as a valuable target for HCC therapy. Experimental Approach: We use lentiviral shMet and selective Met inhibitor PHA665752 to explore the function of Met/cjun/Nanog axi in CD44v6+ cells. The orthotopic liver xenograft tumor model was used to detect self-renewal ability of CD44v6+ cells. Furthermore, a luciferase reporter assay and chromatin immunoprecipitation (ChIP) assay were carried out to find the exact binding site of cjun in the Nanog promoter. Key Results: In this study, we demonstrated that CD44v6+ CSCs not only facilitate the properties of cancer stemness, but also represent the high expression of the HGF/MET signal pathway. Inhibiting the activation of Met in CD44v6+ HCC cells in vidvo and in vitro significantly decrease the expression of cjun and Nanog. Furthermore, we found a binding site of cjun in 1700bp before the transcription start site of Nanog. Conclusion and Implications: The stemness properties of CD44v6+ cells is promoted by the Met/cjun/Nanog signaling pathway. And the cjun is binding in 1700bp before the transcription start site of Nanog.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2022) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: